EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Real-world persistence and compliance of denosumab versus alendronate among postmenopausal women with osteoporosis in Asia–Pacific

Tang Ching Lau, Dong-Gune Chang, Chung-Hwan Chen, Shuang Huang, Edith M C Lau, Sheung-Wai Law, Young-Kyun Lee, Cae Tolman, Laura Canals, See-Hwee Yeo, Jing Yu, Peter R Ebeling

Journal of Bone and Mineral Metabolism · 2026

DOI: 10.1007/s00774-025-01663-2 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Bone and Mineral Metabolism, 2026. Verfasst von Tang Ching Lau und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. Hauptthemen laut MEDLINE: Denosumab, Alendronate, Osteoporosis, Postmenopausal, Bone Density Conservation Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Amgen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

To compare 12-month real-world treatment persistence and compliance in postmenopausal women prescribed denosumab or alendronate for osteoporosis in Asia–Pacific. Materials and methods This prospective cohort study enrolled women aged ≥ 50 years from Australia, Taiwan, South Korea, Hong Kong and Singapore between 2019–2021. Study participants were prescribed bi-annual denosumab injection or weekly alendronate, based on physicians’ decision. Medication persistence and compliance were estimated over 12 months of follow-up. Multivariable logistic regression was used to determine if treatment type (denosumab or alendronate) was significantly associated with persistence and compliance, while adjusting for age, fracture history, baseline BMD, prior osteoporosis treatment, and prior treatment with oral glucocorticoids. Adjusted odds ratios (aORs) and 95% confidence intervals (CIs) were calculated.

Results

Among 686 enrolled women, 580 completed their 12-month visit (301 in denosumab and 279 in alendronate group). At baseline, those in the denosumab group were older and more likely to have received prior osteoporosis treatment. Overall treatment persistence and compliance were 72.4% and 70.7%, respectively. Patients receiving denosumab exhibited higher persistence (82.7% vs. 61.3%, P < 0.001) and compliance (86.0% vs. 54.1%, P < 0.001), versus those on alendronate. Regression results also showed that patients on denosumab were more likely to be persistent (aOR = 3.08; 95% CI 2.04–4.63) and compliant (aOR = 5.32; 95% CI 3.45–8.21) with treatment. Gastrointestinal disorders were more frequently reported in the alendronate group, while bone and joint injuries were more common in the denosumab group.

Conclusion

Postmenopausal women with osteoporosis were more likely to be persistent and compliant with denosumab, compared with weekly oral alendronate.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DenosumabAlendronateOsteoporosis, PostmenopausalBone Density Conservation AgentsHumansFemaleMiddle AgedAgedProspective Studies

Stichwörter der Autor:innen

AlendronateDenosumabMedication complianceMedication persistenceOsteoporosis

Substanzen

DenosumabAlendronateBone Density Conservation Agents

Autor:innen und Institutionen

  • Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
  • Department of Orthopedic Surgery, College of Medicine, Inje University Sanggye Paik Hospital, Inje University, Seoul, South Korea.
  • Department of Orthopedics and Orthopedic Research Center, College of Medicine, Regeneration Medicine and Cell Therapy Research Center, Kaohsiung Municipal Ta-Tung Hospital and Kaohsiung Medical University Hospital, Kaoh…
  • Amgen (Europe) GmbH, Rotkreuz, Switzerland.
  • Hong Kong Orthopaedic and Osteoporosis Center for Treatment and Research, Hong Kong, China.
  • Department of Orthopaedics and Traumatology, The Chinese University of Hong Kong, Hong Kong SAR, China.

Förderung

  • Amgen

Zitieren

APA

Lau, T. C., Chang, D. G., Chen, C. H., Huang, S., Lau, E. M. C., Law, S. W., Lee, Y. K., Tolman, C., Canals, L., Yeo, S. H., Yu, J., & Ebeling, P. R. (2026). Real-world persistence and compliance of denosumab versus alendronate among postmenopausal women with osteoporosis in Asia–Pacific. Journal of Bone and Mineral Metabolism. https://doi.org/10.1007/s00774-025-01663-2

Vancouver

Lau TC, Chang DG, Chen CH, Huang S, Lau EMC, Law SW, et al. Real-world persistence and compliance of denosumab versus alendronate among postmenopausal women with osteoporosis in Asia–Pacific. Journal of Bone and Mineral Metabolism. 2026. doi:10.1007/s00774-025-01663-2

BibTeX
@article{Lau2026,
  author = {Lau, Tang Ching and Chang, Dong-Gune and Chen, Chung-Hwan and Huang, Shuang and Lau, Edith M C and Law, Sheung-Wai and Lee, Young-Kyun and Tolman, Cae and Canals, Laura and Yeo, See-Hwee and Yu, Jing and Ebeling, Peter R},
  title = {Real-world persistence and compliance of denosumab versus alendronate among postmenopausal women with osteoporosis in Asia–Pacific},
  journal = {Journal of Bone and Mineral Metabolism},
  year = {2026},
  doi = {10.1007/s00774-025-01663-2}
}
Kostenlos starten →